At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Pembrolizumab (MK-3475) in Combination With Standard Therapy for Newly Diagnosed Glioblastoma
In Brief
A Phase 2 clinical trial evaluating External Beam Radiation Therapy, Laboratory Biomarker Analysis, and 4 other interventions for Glioblastoma and 2 related conditions. Active but no longer recruiting, targeting 52 participants across 3 sites.
Detailed Summary
This phase II trial studies the side effects and how well pembrolizumab works in combination with standard therapy in treating patients with glioblastoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in the chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving pembrolizumab and standard therapy comprising of temozolomide and radiation therapy may kill tumor cells.
Study Details
Timeline
Interventions
Undergo external beam radiation therapy
Correlative studies
Given IV
Undergo radiation therapy
Given PO
Undergo surgery